Global Interventional Oncology Market Expected to Generate a Revenue of $3,313.5 Million, Rising at a CAGR of 6.7% during the Analysis Timeframe from 2021 to 2028 [170-Pages] | Exclusively Available by Research Dive
March 23, 2022 09:01 ET
|
Research Dive
New York, USA, March 23, 2022 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global interventional oncology market is envisioned to generate a revenue of $3,313.5...
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
March 07, 2022 17:37 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...
Global Interventional Oncology Devices Market, 2021-2030: Opportunities in the Emergence of Local Companies in Asia-Pacific and the Middle East and Africa
December 06, 2021 06:43 ET
|
Research and Markets
Dublin, Dec. 06, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Market Analysis and Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering. The global...
HUTCHMED and AstraZeneca Initiate SAMETA Global Phase III Trial of Savolitinib in Combination with PD-L1 Inhibitor IMFINZI® in Patients with MET-Driven Advanced Papillary Renal Cell Carcinoma
November 01, 2021 00:15 ET
|
HUTCHMED (China) Limited
— Follows multiple global studies of savolitinib in papillary renal cell carcinoma patients including SAVOIR and CALYPSO — — In CALYPSO, savolitinib and IMFINZI® combination demonstrated a 57%...
FDA Approves Phase II Kidney Cancer Therapy Study
September 13, 2021 18:41 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States Food and Drug...
Global $196.96 Bn Oncology Devices Market to 2025 & 2030: Major Players are Eckert & Ziegler BEBIG, Oncura, GE, Medtronic, Varian Medical Systems, Elekta, Theragenics, Accuray, and Roche Diagnostics
August 20, 2021 06:08 ET
|
Research and Markets
Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. The global...
Global $3.32 Bn Interventional Oncology Devices Market to 2030: Embolization Devices, Ablation Devices, & Support Devices
July 16, 2021 05:53 ET
|
Research and Markets
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's...
Global $136.7 Billion Oncology Market to 2025
October 30, 2020 03:13 ET
|
Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Oncology Market - Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. Oncology Market size was valued at $136.7...
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
October 22, 2020 01:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and ISTANBUL, Turkey, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) and Eczacıbaşı-Monrol Nuclear Products Co. (‘Eczacıbaşı...
First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan
August 17, 2020 20:00 ET
|
Telix Pharmaceuticals Limited
TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that...